Adjuvant Treatment for Resected Stage III Melanoma with Axillary Involvement
For completely resected stage III melanoma involving axillary lymph nodes, offer anti-PD-1 immunotherapy (nivolumab or pembrolizumab) for 52 weeks as first-line adjuvant therapy, regardless of BRAF mutation status. 1
Treatment Algorithm by BRAF Status
BRAF Wild-Type Disease
- Nivolumab 240 mg IV every 2 weeks OR 480 mg IV every 4 weeks for 52 weeks
- Pembrolizumab 200 mg IV every 3 weeks for 52 weeks
These are the only recommended options for BRAF wild-type stage III disease 1. Both agents have demonstrated high-quality evidence with strong recommendations based on improved recurrence-free survival in randomized trials 1.
BRAF V600E/K Mutant Disease
You have three evidence-based options 1:
- Nivolumab (same dosing as above)
- Pembrolizumab (same dosing as above)
- Dabrafenib 150 mg PO twice daily + Trametinib 2 mg PO once daily for 52 weeks
The choice between immunotherapy and targeted therapy in BRAF-mutant disease requires weighing specific factors:
Favor anti-PD-1 immunotherapy when:
- Patient prioritizes potential long-term durable responses
- Patient can tolerate intermittent hospital visits for IV infusions
- Lower treatment discontinuation rate is desired (8-10% vs 26% with targeted therapy) 1
- Lower grade 3+ toxicity rate is acceptable (14.4-14.7% vs 41% with targeted therapy) 1
Favor dabrafenib + trametinib when:
- Rapid disease control is critical
- Patient has BRAF V600E/K mutation confirmed
- Patient prefers oral therapy and autonomy in administration 2
- Preliminary overall survival benefit data influences decision 1
Network meta-analysis shows no significant difference in efficacy between these options (HR for dabrafenib/trametinib vs nivolumab 0.88,95% CI 0.59-1.31; vs pembrolizumab 0.91,95% CI 0.57-1.44) 1.
Critical Caveats for Stage IIIA Disease
If your patient has stage IIIA with microscopic sentinel node metastasis <1 mm: Treatment should be individualized after thorough risk-benefit discussion 1. These patients were excluded from pivotal trials, have relatively better prognosis, and lower relapse risk. The potential for serious immune-related toxicity (both acute and long-term) must be carefully weighed against uncertain benefit in this lower-risk subset 1.
Emerging Neoadjuvant Approach
For clinically detectable (palpable) axillary nodes, consider neoadjuvant pembrolizumab as a preferred approach over upfront surgery followed by adjuvant therapy 3. The SWOG S1801 trial demonstrated superior event-free survival with neoadjuvant pembrolizumab (3 doses pre-resection) followed by surgery and adjuvant pembrolizumab (15 additional doses) compared to surgery followed by 18 doses of adjuvant pembrolizumab alone: 72% vs 49% 2-year event-free survival 3. This represents a paradigm shift for clinically node-positive disease.
Neoadjuvant dosing: Pembrolizumab 200 mg IV every 3 weeks for 3 doses pre-surgery, then 15 doses post-surgery 1, 3.
Not Recommended
- Ipilimumab monotherapy is not recommended for routine adjuvant use 1
- High-dose interferon is not recommended for routine adjuvant use 1
- BRAF/MEK inhibitors for non-V600E/K mutations: No recommendation can be made due to lack of data 1
Common Pitfalls
- Don't assume all stage IIIA patients need adjuvant therapy - those with <1 mm sentinel node involvement have excellent prognosis and may not benefit enough to justify toxicity risk
- Don't delay treatment for BRAF testing in wild-type disease - anti-PD-1 is appropriate regardless of mutation status
- Don't use ipilimumab 10 mg/kg as adjuvant therapy - nivolumab and pembrolizumab have superior efficacy and tolerability profiles 4
- Consider neoadjuvant therapy for clinically positive nodes rather than defaulting to upfront surgery - this is now the preferred approach based on S1801 data 3